Starting next week, the first people in Germany will be able to be vaccinated against the corona virus for the third time.
Shortly before the booster vaccinations start, Biontech and Pfizer publish the results of the Phase III study.
From September 1, the time has come: Numerous people in Germany and thus also in Baden-Württemberg can be vaccinated against the corona virus for the third time *, as reported by echo24.de *.
This is already possible in Bavaria.
Only the vaccine from Biontech is used.
Shortly before the start of the booster vaccinations, Biontech and its US partner Pfizer announced that they would like to submit further data to the US FDA for the approval of the third vaccination against the coronavirus.
A phase III study showed that it had “significant neutralizing antibody titers”.
According to Biontech / Pfizer, the application with the new data should be submitted by the end of the week.
Booster vaccination against coronavirus: Phase III study with more subjects
The phase III study plays a key role in the approval of a drug, as
Der Spiegel
reports.
In this way, not only is the effectiveness of the agent checked, but significantly more test subjects also take part.
In the case of Biontech / Pfizer, 306 subjects between the ages of 18 and 55 participated in the study.
The two companies announced that the study participants received the booster vaccinations "between 4.8 and 8 months after completing the double vaccination, with a median follow-up time of 2.6 months after the booster vaccination".
Booster vaccination against coronavirus: Phase III study provides promising data
One month after the third vaccination against the coronavirus, “robust neutralizing antibody titers against the wild-type strain of SARS-CoV-2” could be detected in the test subjects without a proven infection.
The neutralizing antibody titers after the booster dose were 3.3 times as high as the concentration after the second vaccination.
In addition, the vaccination reaction after the new injection was "light to moderate".
“The most common side effects * were injection site pain, fatigue, headache, muscle and joint pain, and chills.
Compared to the reactions after the double vaccination, the incidence of severe systemic side effects after the booster dose was low, ”said Biontech and Pfizer in a press release.
Booster vaccination against coronavirus: Results of the phase III study are also to be presented to the European Medicines Agency
The data from the phase III study will also be submitted to the European Medicines Agency (EMA) and other authorities in the coming weeks.
In addition, it is planned to publish “the data in a specialist journal with a peer review process”.
+
In Germany, the booster vaccinations will start in the coming week.
© Marijan Murat / dpa
A third dose of the Pfizer Biontech vaccine is not currently approved for general use in the United States.
On August 12, however, a third dose was approved as part of the Extended Emergency Authorization (EUA) for use in people aged 12 and over who have had an organ transplant or who have been diagnosed with a health condition that is equivalent to an immunodeficiency.
In Germany and Baden-Württemberg, the booster vaccinations will start in the coming week, but initially only for certain people *.
Booster vaccination against coronavirus: World Health Organization advocates better distribution of vaccines
From an epidemiological point of view, it is hoped that the booster vaccinations will provide even better protection against Covid-19 for people who are particularly likely to be severe or even fatal. In addition, the spread of the coronavirus in the population should be curbed even better.
From the point of view of the World Health Organization (WHO), however, vaccines should first be delivered to poorer countries before third-party vaccinations are started in the industrialized countries.
After all, there are still many countries whose vaccination rate is very low due to the lack of vaccine.
Ultimately, this is also a pity for the states with good vaccination rates, as the virus continues to spread and new mutations are more likely.
These could then at some point bypass the vaccination protection.
* echo24.de is an offer from
IPPEN.MEDIA
List of rubric lists: © Marijan Murat / dpa